| Product Code: ETC12962926 | Publication Date: Apr 2025 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Taiwan Naltrexone Buprenorphine Market Overview |
3.1 Taiwan Country Macro Economic Indicators |
3.2 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, 2021 & 2031F |
3.3 Taiwan Naltrexone Buprenorphine Market - Industry Life Cycle |
3.4 Taiwan Naltrexone Buprenorphine Market - Porter's Five Forces |
3.5 Taiwan Naltrexone Buprenorphine Market Revenues & Volume Share, By Formulation Type, 2021 & 2031F |
3.6 Taiwan Naltrexone Buprenorphine Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.7 Taiwan Naltrexone Buprenorphine Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Taiwan Naltrexone Buprenorphine Market Revenues & Volume Share, By Administration Method, 2021 & 2031F |
3.9 Taiwan Naltrexone Buprenorphine Market Revenues & Volume Share, By Patient Group, 2021 & 2031F |
4 Taiwan Naltrexone Buprenorphine Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about the benefits of naltrexone and buprenorphine in treating opioid addiction |
4.2.2 Rising prevalence of opioid addiction in Taiwan |
4.2.3 Government initiatives and policies promoting the use of naltrexone and buprenorphine in addiction treatment |
4.3 Market Restraints |
4.3.1 Stringent regulations and guidelines for the use of naltrexone and buprenorphine |
4.3.2 Limited access to healthcare facilities providing naltrexone and buprenorphine treatment |
4.3.3 Stigma associated with medication-assisted treatment for opioid addiction |
5 Taiwan Naltrexone Buprenorphine Market Trends |
6 Taiwan Naltrexone Buprenorphine Market, By Types |
6.1 Taiwan Naltrexone Buprenorphine Market, By Formulation Type |
6.1.1 Overview and Analysis |
6.1.2 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Formulation Type, 2021 - 2031F |
6.1.3 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Oral Tablet, 2021 - 2031F |
6.1.4 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Sublingual Film, 2021 - 2031F |
6.1.5 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Injectable Form, 2021 - 2031F |
6.1.6 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Implant, 2021 - 2031F |
6.1.7 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Combination Form, 2021 - 2031F |
6.2 Taiwan Naltrexone Buprenorphine Market, By Mechanism of Action |
6.2.1 Overview and Analysis |
6.2.2 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Opioid Receptor Modulation, 2021 - 2031F |
6.2.3 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Partial Agonist, 2021 - 2031F |
6.2.4 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Long-Acting Effect, 2021 - 2031F |
6.2.5 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Sustained Release, 2021 - 2031F |
6.2.6 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Dual Mechanism, 2021 - 2031F |
6.3 Taiwan Naltrexone Buprenorphine Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Opioid Dependence, 2021 - 2031F |
6.3.3 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Withdrawal Management, 2021 - 2031F |
6.3.4 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Relapse Prevention, 2021 - 2031F |
6.3.5 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Maintenance Therapy, 2021 - 2031F |
6.3.6 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Detoxification, 2021 - 2031F |
6.4 Taiwan Naltrexone Buprenorphine Market, By Administration Method |
6.4.1 Overview and Analysis |
6.4.2 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Oral, 2021 - 2031F |
6.4.3 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Sublingual, 2021 - 2031F |
6.4.4 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Injection, 2021 - 2031F |
6.4.5 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Subcutaneous, 2021 - 2031F |
6.4.6 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Oral, 2021 - 2031F |
6.5 Taiwan Naltrexone Buprenorphine Market, By Patient Group |
6.5.1 Overview and Analysis |
6.5.2 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Adults, 2021 - 2031F |
6.5.3 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Teenagers, 2021 - 2031F |
6.5.4 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Elderly, 2021 - 2031F |
6.5.5 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By Critical Patients, 2021 - 2031F |
6.5.6 Taiwan Naltrexone Buprenorphine Market Revenues & Volume, By All Ages, 2021 - 2031F |
7 Taiwan Naltrexone Buprenorphine Market Import-Export Trade Statistics |
7.1 Taiwan Naltrexone Buprenorphine Market Export to Major Countries |
7.2 Taiwan Naltrexone Buprenorphine Market Imports from Major Countries |
8 Taiwan Naltrexone Buprenorphine Market Key Performance Indicators |
8.1 Number of healthcare providers trained in prescribing and administering naltrexone and buprenorphine |
8.2 Patient enrollment and retention rates in naltrexone and buprenorphine treatment programs |
8.3 Adherence rates to naltrexone and buprenorphine treatment protocols |
8.4 Rate of successful outcomes in terms of reduced opioid use and improved quality of life among patients undergoing naltrexone and buprenorphine treatment |
9 Taiwan Naltrexone Buprenorphine Market - Opportunity Assessment |
9.1 Taiwan Naltrexone Buprenorphine Market Opportunity Assessment, By Formulation Type, 2021 & 2031F |
9.2 Taiwan Naltrexone Buprenorphine Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
9.3 Taiwan Naltrexone Buprenorphine Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Taiwan Naltrexone Buprenorphine Market Opportunity Assessment, By Administration Method, 2021 & 2031F |
9.5 Taiwan Naltrexone Buprenorphine Market Opportunity Assessment, By Patient Group, 2021 & 2031F |
10 Taiwan Naltrexone Buprenorphine Market - Competitive Landscape |
10.1 Taiwan Naltrexone Buprenorphine Market Revenue Share, By Companies, 2024 |
10.2 Taiwan Naltrexone Buprenorphine Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here